Skip to main content

Table 4 Detailed characteristics of included studies

From: Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis

Author Year Number of patients Disease stage NLR cutoff value Median age (years) Breast cancer subtype (%) Grade (%) Postmenopausal (%) Median follow-up (years)
ER+ HER-2+ Triple negative Grade 1–2 Grade 3
Asano et al. [12] 2016 61 Early 3.0 n/a 0 0 100 72 28 36 3.1
Azab et al. [23] 2012 316 Mixed 3.3 n/a 83 17 n/a 70 30 n/a 3.8
Azab et al. [13] 2013 437 Mixed 3.3 64 76 n/a n/a n/a n/a n/a 5
Bozkurt et al. [24] 2015 85 Early 2.0 n/a 0 0 100 31 69 69 n/a
Dirican et al. [25] 2015 1527 Mixed 4.0 n/a 68 17 n/a 80 20 44 2.5
Forget et al. [10] 2014 720 Early 3.3 n/a 84 9 n/a 61 39 n/a 5.8
Hong et al. [29] 2015 487 Early 1.9 55 67 21 19 73 27 42 4.6
Jia et al. [14] 2015 1570 Early 2.0 47 n/a 22 14 62 38 n/a 6.6
Koh et al. [8] 2014 157 Early 2.3 44 n/a 0 0 80 20 n/a 1.8
Koh et al. [15] 2015 1435 Mixed 5.0 52 55 36 100 56 44 n/a n/a
Nakano et al. [9] 2015 167 Early 2.5 58 78 18 n/a 80 20 25 7.2a
Noh et al. [26] 2013 442 Early 2.5 50 71 29 18 71 29 n/a 5.9
Pistelli et al. [27] 2015 90 Early 3.0 53 0 0 100 10 90 40 4.5
Rimando et al. [28] 2016 461 Mixed 3.8 58 74 n/a n/a 51 49 n/a 5.1
Yao et al. [11] 2014 608 Early 2.6 53 66 25 16 n/a n/a 48 3.5
  1. ER estrogen receptor, n/a not available, NLR neutrophil-to-lymphocyte
  2. aMean follow-up